ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Novitium entered into deal with Eton Pharmaceuticals to distribute a generic CARBAGLU (Carglumic Acid) with a 50% split of the profits

Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid

According to Eton's Q3 earnings conference call:

The second product driving our Q3 revenue growth was carglumic acid. We continue to see a strong reception for the product with revenue increasing 40% over the prior quarter. Carglumic acid is a lower cost alternative to CARBAGLU and with the cost of CARBAGLU exceeding $1 million annually for some patients, prescribers have been very excited that we brought a lower cost alternative to market, while still offering the patient support services that they have grown accustomed to for rare disease products.

The prescribers and patients also appreciate the fact that our tablets do not require refrigeration, which provides an additional convenience benefit to patients. Carglumic acid tablets have now been commercially available for three full quarters, and we believe we remain on track to capture approximately 25% to 35% market share of the estimated $50 million plus market.

The Carglumic Acid market is projected to grow from $124 million to $300 million from 2020 to 2031. The 50 million Market could grow to over $120 million. If tablets keep pace with the overall growth on Carglumic Acid Market, ANIP could be looking at close to $20 million in royalty payments from Eton by 2031.

Carglumic market report